A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination With the FLT3 Inhibitor Gilteritinib, in Patients With FLT3-mutated Relapsed or Refractory AML
Latest Information Update: 24 Apr 2024
At a glance
- Drugs Gilteritinib (Primary) ; Lanraplenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Kronos Bio
- 19 Apr 2024 Status changed from active, no longer recruiting to discontinued as per sponsor's decision.
- 14 Mar 2024 This trial has been Discontinued in Spain, according to European Clinical Trials Database record.
- 27 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 May 2024.